AGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

AGENUS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026

$6.18+0.14 (+2.32%)

Close on Oct 19, 2026

Market cap: $255.47M
P/E (TTM): –
Dividend yield: –

Dividends

Agenus has not reported a dividend

No dividend per share appears in Agenus's annual filings since fiscal 2010.

Where these numbers come from

Parsed from the XBRL in Agenus's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-20 reverse split on Apr 12, 2024
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AGEN.

Revenue growth30.5% · median 85.4%

Operating margin27.3% · median -226.5%

Company	Revenue	Growth
RGNX	$174.48M	+12.0%
BEAM	$156.04M	+158.9%
AGEN	$132.69M	+30.5%
AUTL	$117.39M	+292.2%
DNA	$111.86M	-46.8%
CGEN	–	–

Company

Next earnings (est.): Nov 9, 2026, before open
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 81
Held by institutions: 31.7%
Auditor: KPMG LLP
SEC CIK: 1098972

Advertisement
300 × 250